Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Koshine Biomedica is a subsidiary of Kintor Pharmaceutical focused on dermatology and cosmeceutical innovation. Its lead clinical program is pyrilutamide (KX‑826), an androgen receptor antagonist in late-stage clinical trials for androgenetic alopecia and acne. The company has recently pivoted to commercializing over-the-counter cosmetic treatments such as freckle-removing creams and whitening essences based on its pipeline compounds due to financial constraints at the parent level. Clinical results show promising safety and efficacy data for long-term use of pyrilutamide in hair loss.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Suzhou Koshine Biomedica.